GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

A. Venditti, A. Piciocchi, A. Candoni, L. Melillo, V. Calafiore, R. Cairoli, P. De Fabritiis, G. Storti, P. Salutari, F. Lanza, G. Martinelli, M. Luppi, P. Mazza, M.P. Martelli, A. Cuneo, F. Albano, F. Fabbiano, A. Tafuri, A. Chierichini, A. TieghiN.S. Fracchiolla, D. Capelli, R. Foà, C. Alati, E.L. Sala, P. Fazi, M. Vignetti, L. Maurillo, F. Buccisano, M.I. Del Principe, M. Irno-Consalvo, T. Ottone, S. Lavorgna, M.T. Voso, F. Lo-Coco, W. Arcese, S. Amadori

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds